101 related articles for article (PubMed ID: 1713038)
21. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation.
Cho KJ; Vinik AI
Radiology; 1990 Nov; 177(2):549-53. PubMed ID: 2171015
[TBL] [Abstract][Full Text] [Related]
22. [Use of octreotide in the treatment of digestive endocrine tumors. A French multicenter study].
Blanchin M; James-Deidier A; Chaumet-Riffaud PD; Chayvialle JA
Presse Med; 1992 Apr; 21(15):697-702. PubMed ID: 1376476
[TBL] [Abstract][Full Text] [Related]
23. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
Biesma B; Willemse PH; Mulder NH; Verschueren RC; Kema IP; de Bruijn HW; Postmus PE; Sleijfer DT; de Vries EG
Br J Cancer; 1992 Nov; 66(5):850-5. PubMed ID: 1384643
[TBL] [Abstract][Full Text] [Related]
24. Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide.
Joensuu H; Kätkä K; Kujari H
Acta Endocrinol (Copenh); 1992 Feb; 126(2):184-5. PubMed ID: 1371898
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
[TBL] [Abstract][Full Text] [Related]
26. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial.
Jacobsen MB; Hanssen LE
J Intern Med; 1995 Mar; 237(3):269-75. PubMed ID: 7534331
[TBL] [Abstract][Full Text] [Related]
27. Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours.
Schöber C; Schmoll E; Schmoll HJ; Poliwoda H; Schuppert F; Stahl M; Bokemeyer C; Wilke H; Weiss J
Eur J Cancer; 1992; 28A(10):1664-6. PubMed ID: 1382494
[TBL] [Abstract][Full Text] [Related]
28. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
Lissoni P; Barni S; Tancini G; Mainini E; Piglia F; Maestroni GJ; Lewinski A
Oncology; 1995; 52(2):163-6. PubMed ID: 7854778
[TBL] [Abstract][Full Text] [Related]
29. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
Linkesch M; Kuzmits R; Geyer G
Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
[TBL] [Abstract][Full Text] [Related]
30. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour.
Veenhof CH; de Wit R; Taal BG; Dirix LY; Wagstaff J; Hensen A; Huldij AC; Bakker PJ
Eur J Cancer; 1992; 28(1):75-8. PubMed ID: 1373635
[TBL] [Abstract][Full Text] [Related]
31. Treatment of carcinoid syndrome with recombinant interferon alpha-2a.
Di Bartolomeo M; Bajetta E; Zilembo N; de Braud F; Di Leo A; Verusio C; D'Aprile M; Scanni A; Barduagni M; Barduagni A [corrected to Barduagni M]
Acta Oncol; 1993; 32(2):235-8. PubMed ID: 7686766
[TBL] [Abstract][Full Text] [Related]
32. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
Oberg K; Norheim I; Theodorsson E
Acta Oncol; 1991; 30(4):503-7. PubMed ID: 1854508
[TBL] [Abstract][Full Text] [Related]
33. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results.
Oberg K; Norheim I; Lind E; Alm G; Lundqvist G; Wide L; Jonsdottir B; Magnusson A; Wilander E
Cancer Treat Rep; 1986 Nov; 70(11):1297-304. PubMed ID: 2429764
[TBL] [Abstract][Full Text] [Related]
34. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?
Välimäki M; Järvinen H; Salmela P; Sane T; Sjöblom SM; Pelkonen R
Cancer; 1991 Feb; 67(3):547-9. PubMed ID: 1702352
[TBL] [Abstract][Full Text] [Related]
35. [Intracerebral metastasis of a bronchial carcinoid tumor].
Ohnsmann A; Sachsenheimer W
Neurochirurgia (Stuttg); 1992 Sep; 35(5):160-2. PubMed ID: 1436366
[TBL] [Abstract][Full Text] [Related]
36. Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide.
Antonelli A; Gambuzza C; Bertoni F; Baschieri L
Clin Ther; 1992; 14(2):178-84. PubMed ID: 1377097
[TBL] [Abstract][Full Text] [Related]
37. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic strategies in the management of endocrine GEP tumours.
Arnold R
Eur J Clin Invest; 1990 Oct; 20 Suppl 1():S82-90. PubMed ID: 1702388
[TBL] [Abstract][Full Text] [Related]
39. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group.
Arnold R; Benning R; Neuhaus C; Rolwage M; Trautmann ME
Digestion; 1993; 54 Suppl 1():72-5. PubMed ID: 8359572
[TBL] [Abstract][Full Text] [Related]
40. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha.
Doberauer C; Mengelkoch B; Kloke O; Wandl U; Niederle N
Acta Oncol; 1991; 30(5):603-5. PubMed ID: 1892678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]